Cargando…

Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities

PURPOSE OF REVIEW: As the costs of genomic testing have fallen, and our understanding of genetic susceptibility to cancers has grown, there has been increasing interest in incorporating testing for cancer susceptibility genes, and polygenic risk estimates, into population cancer screening. A growing...

Descripción completa

Detalles Bibliográficos
Autores principales: Briggs, Sarah, Slade, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019642/
https://www.ncbi.nlm.nih.gov/pubmed/32117599
http://dx.doi.org/10.1007/s40142-019-00162-x
_version_ 1783497566907793408
author Briggs, Sarah
Slade, Ingrid
author_facet Briggs, Sarah
Slade, Ingrid
author_sort Briggs, Sarah
collection PubMed
description PURPOSE OF REVIEW: As the costs of genomic testing have fallen, and our understanding of genetic susceptibility to cancers has grown, there has been increasing interest in incorporating testing for cancer susceptibility genes, and polygenic risk estimates, into population cancer screening. A growing body of evidence suggests that this would be both clinically and cost-effective. In this article, we aim to explore the frameworks used to evaluate screening programmes, evaluate whether population screening for cancer susceptibility can be assessed using these standards, and consider additional issues and outcomes of importance in this context. RECENT FINDINGS: There are tensions between traditional approaches of genetic testing (utilising tests with high sensitivity and specificity) and the principles of population screening (in which the screening test typically has low specificity), as well as the frameworks used to evaluate the two. Despite the existence of many screening guidelines, including consensus papers, these often do not align fully with broader considerations of genetic test evaluation. Population screening for genetic risk in cancer shifts the focus from diagnostics to prognostication and has wider implications for personal and familial health than existing screening programmes. In addition, understanding of the prevalence and penetrance of cancer susceptibility genes, required by many screening guidelines, may only be obtainable through population-level testing; prospective multi-disciplinary research alongside implementation will be essential. SUMMARY: Appropriate evaluation of genetic screening for cancer risk will require modification of existing screening frameworks to incorporate additional complexity of outcomes and population values. As evidence supporting population screening for cancer susceptibility mounts, development of an appropriate evaluative framework, and expansion of public dialogue will be key to informing policy.
format Online
Article
Text
id pubmed-7019642
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-70196422020-02-28 Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities Briggs, Sarah Slade, Ingrid Curr Genet Med Rep Cancer Genomics (K Snape and H Hanson, Section Editors) PURPOSE OF REVIEW: As the costs of genomic testing have fallen, and our understanding of genetic susceptibility to cancers has grown, there has been increasing interest in incorporating testing for cancer susceptibility genes, and polygenic risk estimates, into population cancer screening. A growing body of evidence suggests that this would be both clinically and cost-effective. In this article, we aim to explore the frameworks used to evaluate screening programmes, evaluate whether population screening for cancer susceptibility can be assessed using these standards, and consider additional issues and outcomes of importance in this context. RECENT FINDINGS: There are tensions between traditional approaches of genetic testing (utilising tests with high sensitivity and specificity) and the principles of population screening (in which the screening test typically has low specificity), as well as the frameworks used to evaluate the two. Despite the existence of many screening guidelines, including consensus papers, these often do not align fully with broader considerations of genetic test evaluation. Population screening for genetic risk in cancer shifts the focus from diagnostics to prognostication and has wider implications for personal and familial health than existing screening programmes. In addition, understanding of the prevalence and penetrance of cancer susceptibility genes, required by many screening guidelines, may only be obtainable through population-level testing; prospective multi-disciplinary research alongside implementation will be essential. SUMMARY: Appropriate evaluation of genetic screening for cancer risk will require modification of existing screening frameworks to incorporate additional complexity of outcomes and population values. As evidence supporting population screening for cancer susceptibility mounts, development of an appropriate evaluative framework, and expansion of public dialogue will be key to informing policy. Springer US 2019-05-18 2019 /pmc/articles/PMC7019642/ /pubmed/32117599 http://dx.doi.org/10.1007/s40142-019-00162-x Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Cancer Genomics (K Snape and H Hanson, Section Editors)
Briggs, Sarah
Slade, Ingrid
Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities
title Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities
title_full Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities
title_fullStr Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities
title_full_unstemmed Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities
title_short Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities
title_sort evaluating the integration of genomics into cancer screening programmes: challenges and opportunities
topic Cancer Genomics (K Snape and H Hanson, Section Editors)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019642/
https://www.ncbi.nlm.nih.gov/pubmed/32117599
http://dx.doi.org/10.1007/s40142-019-00162-x
work_keys_str_mv AT briggssarah evaluatingtheintegrationofgenomicsintocancerscreeningprogrammeschallengesandopportunities
AT sladeingrid evaluatingtheintegrationofgenomicsintocancerscreeningprogrammeschallengesandopportunities